This POC company is going anywhere?? Management is just too stupid and ignorant to know to use this ruling as a negotiation tool by threatening bankruptcy. The management and CEO of this company should just disappear. They ruined a perfectly good opportunity with this drug.
At the very least, perhaps this decision has at least opened SIGA's eyes to need to discuss settlement. In the past, I think they were overly confident in their position. To be honest I was uncertain enough with length of Parsons last review on remand that I got nervous toward the end and was hedging my PIP position with SIGA calls. After this decision I think both companies may be more willing to consider a settlement and uncertainty regarding claims to the assets in BK will be reason enough for PIP to consider.
As much as I have said I would not buy SIGA at this point, due to the overhang and lengthy delay between timing for final judgment and potential for new BARDA order, I still think ST-246 has significant value in the next 2-3 years. In testimony before FDA Advisory Committee meeting (testimony by Director, Office of Public Health Preparedness and Response) a few years back, it was clear that U.S. wants to support development of two antivirals to FDA approval. Not crazy then to think that BARDA will split stockpile to include both. If 14 million courses was right number from SIGA's first contract, which was cut back to 2 mln, then they it would seem they should get at least 5 mln from next round of BARDA orders. I think PIP would agree and see value in giving up a portion of the damage award (especially if it appears unlikely they could collect on it in the relatively near term) in return for a stake in future of ST-246.